J&J highlighted updated data from arm 1 (recurrent, BCG-unresponsive HR NMIBC) & 3 (recurrent intermediate-risk NMIBC) of the P-I study investigating TAR-210’s safety & efficacy to treat NMIBC with select FGFR alterations at AUA 2024. Initial findings were presented at ESMO 2023 followed by interim updates at EAU 2024
In the study 64 patients received TAR-210 across both arms. The data, as of Mar 2024, showed a 12mos. RF survival rate of 90% in arm 1 (n=21) & CR rate of 90% in arm 3 (n=31) without any DLTs or deaths; 2 patients each discontinued due to TEAEs & 2 patients had TEAEs & serious TEAEs
TAR-210 is an intravesical system offering sustained and local release of erdafitinib directly into the bladder for treating NMIBC
Ref: Johnson & Johnson | Image: Johnson & Johnson
Related News:- Johnson & Johnson’s Sirturo Gains the CHMP’s Positive Opinion to Treat Multidrug-Resistant Tuberculosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
